Multiple Sclerosis

Multiple sclerosis is a chronic immune-mediated disease of the central nervous system in which inflammation, demyelination, and neurodegeneration damage the brain, optic nerves, and spinal cord. It typically begins in young adults and produces variable neurological symptoms disseminated in space and time, ranging from visual and sensory disturbances to motor and cognitive impairment.

Definition

Multiple sclerosis is a chronic immune-mediated disorder of the central nervous system characterised by inflammatory demyelinating lesions and progressive neuroaxonal degeneration, producing neurological dysfunction disseminated in space (multiple sites) and in time (multiple episodes or progression).

Scope

This entry covers the immune-mediated demyelinating pathology of multiple sclerosis, its clinical course types (relapsing-remitting and progressive), the principle of dissemination in space and time, the role of MRI and diagnostic criteria, and its epidemiology. It is positioned here for its neurodegenerative component; it differs from the protein-aggregation disorders in this family in being primarily inflammatory and immune-mediated. It is a reference overview, not clinical guidance for any individual.

Core questions

• How do inflammation, demyelination, and neurodegeneration interact over the disease course?
• What distinguishes relapsing from progressive disease biology?
• How is dissemination in space and time established for diagnosis?
• What drives the transition from relapsing to progressive disability?

Key concepts

• Inflammatory demyelination and plaques
• Relapsing-remitting course
• Primary and secondary progressive course
• Dissemination in space and in time
• McDonald diagnostic criteria and MRI
• Oligoclonal bands in cerebrospinal fluid
• Neuroaxonal degeneration and progressive disability

Key theories

Immune-mediated demyelination

Multiple sclerosis is understood as an immune-mediated disorder in which immune cells attack central nervous system myelin, producing the characteristic inflammatory demyelinating plaques; this framework underlies its classification distinct from the protein-aggregation neurodegenerative diseases.

Dissemination in space and time

The diagnostic logic of multiple sclerosis rests on demonstrating central nervous system lesions disseminated in space (multiple anatomical sites) and in time (multiple events or ongoing activity), a principle formalised and operationalised with MRI in the McDonald criteria.

Mechanisms

In multiple sclerosis, immune-mediated inflammation damages myelin and the oligodendrocytes that produce it, forming demyelinating plaques throughout the central nervous system white and grey matter. Acute inflammatory lesions can cause relapses with partial recovery, while accumulating axonal and neuronal injury underlies progressive, often irreversible disability. The relapsing-remitting phase is dominated by focal inflammation, whereas the progressive phase reflects a greater contribution of diffuse neurodegeneration. Diagnosis hinges on demonstrating lesions disseminated in space and time, with MRI and cerebrospinal fluid findings supporting the clinical picture (Reich et al., 2018; Thompson et al., 2018).

Clinical relevance

Multiple sclerosis is a leading cause of non-traumatic neurological disability in young adults, and the principles of dissemination in space and time, supported by MRI and cerebrospinal fluid analysis, structure how it is recognised. Distinguishing relapsing from progressive courses shapes how the disease is conceptualised. This entry describes how the disease is understood and classified; it is not a basis for individual diagnostic or treatment decisions.

Epidemiology

Multiple sclerosis most often begins between the third and fifth decades of life and is more common in women than men. Its prevalence varies geographically, generally increasing with distance from the equator, a gradient that has implicated environmental factors such as vitamin D status and Epstein-Barr virus exposure alongside genetic susceptibility (Reich et al., 2018).

History

Jean-Martin Charcot gave the first detailed clinicopathological account of multiple sclerosis in the 1860s, linking the disseminated plaques to the clinical syndrome. Through the twentieth century the disease was recognised as immune-mediated and classified into relapsing and progressive courses. The advent of MRI and the development and successive revisions of the McDonald criteria (Thompson et al., 2018) transformed diagnosis by allowing dissemination in space and time to be demonstrated earlier and more reliably.

Debates

What drives progression independent of relapses?

The relative contributions of ongoing focal inflammation versus diffuse, compartmentalised neurodegeneration to progressive disability, and how to define and measure progression independent of relapse activity, remain actively debated.

Where does multiple sclerosis sit among neurological diseases?

Although grouped here for its neurodegenerative component, multiple sclerosis is fundamentally an immune-mediated demyelinating disease, and its classification straddles inflammatory and neurodegenerative categories.

Key figures

• Jean-Martin Charcot
• Daniel S. Reich
• Claudia F. Lucchinetti
• Alan J. Thompson
• Peter A. Calabresi

Seminal works

• reich-2018
• thompson-2018

Frequently asked questions

Is multiple sclerosis a neurodegenerative or an inflammatory disease?

It is primarily an immune-mediated, inflammatory demyelinating disease of the central nervous system, but it also involves progressive neuroaxonal degeneration that drives much of the long-term disability, so it bridges inflammatory and neurodegenerative categories.

What does 'dissemination in space and time' mean?

It is the diagnostic principle that multiple sclerosis affects multiple parts of the central nervous system (in space) on more than one occasion or in an ongoing way (in time); demonstrating this pattern, often with MRI, is central to the McDonald diagnostic criteria.